198 related articles for article (PubMed ID: 37283935)
1. Neurooncology: 2023 update.
Mittelbronn M
Free Neuropathol; 2023 Jan; 4():. PubMed ID: 37283935
[TBL] [Abstract][Full Text] [Related]
2. Multi-institutional noninvasive in vivo characterization of
Rathore S; Mohan S; Bakas S; Sako C; Badve C; Pati S; Singh A; Bounias D; Ngo P; Akbari H; Gastounioti A; Bergman M; Bilello M; Shinohara RT; Yushkevich P; O'Rourke DM; Sloan AE; Kontos D; Nasrallah MP; Barnholtz-Sloan JS; Davatzikos C
Neurooncol Adv; 2020 Dec; 2(Suppl 4):iv22-iv34. PubMed ID: 33521638
[TBL] [Abstract][Full Text] [Related]
3. Top ten discoveries of the year: Neurooncology.
Wesseling P
Free Neuropathol; 2020 Jan; 1():. PubMed ID: 37283662
[TBL] [Abstract][Full Text] [Related]
4. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.
Weller M; Stupp R; Hegi ME; van den Bent M; Tonn JC; Sanson M; Wick W; Reifenberger G
Neuro Oncol; 2012 Sep; 14 Suppl 4(Suppl 4):iv100-8. PubMed ID: 23095825
[TBL] [Abstract][Full Text] [Related]
5. [Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin].
Molnár P; Méhes G
Magy Onkol; 2009 Mar; 53(1):33-8. PubMed ID: 19318324
[TBL] [Abstract][Full Text] [Related]
6. Molecular Classification of Diffuse Gliomas.
Kalidindi N; Or R; Babak S; Mason W
Can J Neurol Sci; 2020 Jul; 47(4):464-473. PubMed ID: 31918786
[TBL] [Abstract][Full Text] [Related]
7. [Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version].
Malzkorn B; Reifenberger G
Pathologe; 2019 Mar; 40(2):131-139. PubMed ID: 30790013
[TBL] [Abstract][Full Text] [Related]
8. High-grade glioma with pleomorphic and pseudopapillary features (HPAP): a proposed type of circumscribed glioma in adults harboring frequent TP53 mutations and recurrent monosomy 13.
Pratt D; Abdullaev Z; Papanicolau-Sengos A; Ketchum C; Panneer Selvam P; Chung HJ; Lee I; Raffeld M; Gilbert MR; Armstrong TS; Pytel P; Borys E; Klonoski JM; McCord M; Horbinski C; Brat D; Perry A; Solomon D; Eberhart C; Giannini C; Quezado M; Aldape K
Acta Neuropathol; 2022 Mar; 143(3):403-414. PubMed ID: 35103816
[TBL] [Abstract][Full Text] [Related]
9. Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.
Schiff D; Van den Bent M; Vogelbaum MA; Wick W; Miller CR; Taphoorn M; Pope W; Brown PD; Platten M; Jalali R; Armstrong T; Wen PY
Neuro Oncol; 2019 Jul; 21(7):837-853. PubMed ID: 30753579
[TBL] [Abstract][Full Text] [Related]
10. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.
Ballester LY; Huse JT; Tang G; Fuller GN
Hum Pathol; 2017 Nov; 69():15-22. PubMed ID: 28549927
[TBL] [Abstract][Full Text] [Related]
11. [Interdisciplinary neuro-oncology: part 1: diagnostics and operative therapy of primary brain tumors].
Tabatabai G; Hattingen E; Schlegel J; Stummer W; Schlegel U
Nervenarzt; 2014 Aug; 85(8):965-75. PubMed ID: 25037493
[TBL] [Abstract][Full Text] [Related]
12. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
14. FISH analyses for 1p and 19q status on gliomas: Reporting an 8 years' experience from a tertiary care center in the Middle East.
Massaad E; Tabbarah A; Barmada M; Rbeiz J; Nasser S; Farra C
Ann Diagn Pathol; 2022 Apr; 57():151899. PubMed ID: 35063798
[TBL] [Abstract][Full Text] [Related]
15. Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities.
Wood MD; Halfpenny AM; Moore SR
Diagn Pathol; 2019 Apr; 14(1):29. PubMed ID: 30967140
[TBL] [Abstract][Full Text] [Related]
16. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
[TBL] [Abstract][Full Text] [Related]
17. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.
Boots-Sprenger SH; Sijben A; Rijntjes J; Tops BB; Idema AJ; Rivera AL; Bleeker FE; Gijtenbeek AM; Diefes K; Heathcock L; Aldape KD; Jeuken JW; Wesseling P
Mod Pathol; 2013 Jul; 26(7):922-9. PubMed ID: 23429602
[TBL] [Abstract][Full Text] [Related]
18. [Interdisciplinary neuro-oncology: part 2: systemic therapy of primary brain tumors].
Tabatabai G; Hattingen E; Schlegel J; Stummer W; Schlegel U
Nervenarzt; 2014 Aug; 85(8):976-81. PubMed ID: 25037494
[TBL] [Abstract][Full Text] [Related]
19. Input of molecular analysis in medical management of primary brain tumor patients.
Idbaih A; Duran-Peña A; Bonnet C; Ducray F
Rev Neurol (Paris); 2015; 171(6-7):457-65. PubMed ID: 26026669
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy of brain tumors in aduts].
Roth P; Weller M
Nervenarzt; 2015 Apr; 86(4):495-505; quiz 506-7. PubMed ID: 25783972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
